Global Orphan Drugs Market Report: 2016 Edition - New Report by Koncept Analytics - PowerPoint PPT Presentation

Loading...

PPT – Global Orphan Drugs Market Report: 2016 Edition - New Report by Koncept Analytics PowerPoint presentation | free to download - id: 7fb259-YTRiY



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Global Orphan Drugs Market Report: 2016 Edition - New Report by Koncept Analytics

Description:

The report, “Global Orphan Drugs Market” analyzes the current prevailing condition. For more mail: vikas@konceptanalytics.com – PowerPoint PPT presentation

Number of Views:15

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Global Orphan Drugs Market Report: 2016 Edition - New Report by Koncept Analytics


1
Global Orphan Drugs Market Report
----------------------------------------- 2016
View Report Details
2
View Report Details
  • Executive Summary
  • A rare disease is the one that occurs uncommonly
    or rarely in the general population. However,
    there exists no clear definition for categorizing
    rare diseases and is usually defined on the
    basis of the prevalence, and some other factors
    including the severity of disease and
    availability of treatment options. Rare diseases
    are often serious, chronic and progressive.
    Orphan drugs are medicinal products intended for
    the diagnosis, prevention or treatment of rare
    diseases. These drugs are referred to be orphan
    as under normal conditions because these drugs
    are not cost effective to be developed by the
    pharmaceuticals industry, intended for a small
    number of patients suffering from rare
    conditions.
  • Increasing sales of prescription drugs,
    substantial benefits for new entrants in rare
    disease drug market, increased spending on
    medicines, rising healthcare expenditure and
    improving economic conditions of nations are some
    of the significant factors driving growth of the
    Orphan drugs market. However, the growth of the
    market is hindered by certain challenges
    including tougher regulatory approvals,
    limitation on charging higher prices and no
    approved drugs for several rare diseases
    including Polychethemia Vera (PV).
  • The global orphan drugs market is expected to see
    numerous developments including approval of
    several Ultra-Rare drugs, increasing scope of
    Gene therapy, development of drugs for rare blood
    disease, higher success prospects for Hematology
    compared to Solid Tumors, attractive pricing
    option for orphan drug competitors and striking
    opportunities in developing orphan drugs.
  • The report, Global Orphan Drugs Market analyzes
    the current prevailing condition of the market
    along with its future scope of development. The
    global market along with specific market of the
    U.S., Canada, Europe and Japan, is being
    discussed in the report. The major trends, growth
    drivers as well as issues being faced by the
    industry are being presented in this report. The
    major players in the industry are being profiled,
    along with their key financials and strategies
    for growth.

3
The development of orphan drugs has become an
important and attractive research and development
strategy of many pharmaceutical companies, as it
most commonly generates greater profitability due
to the recent development drivers
Global Orphan Drugs Market (2010-2015E)
  • The global market for orphan drugs was estimated
    to have reached US... billion in the year 2015,
    increasing from US.. billion in the previous
    fiscal year recording an annual growth of for
    the year.
  • For the year 2014, share of the overall orphan
    drugs market was held by biological orphan drugs
    followed by non-biological orphan drugs that held
    rest of the .. share.
  • The average cost per person for an orphan and
    non-orphan drug was nearly US... thousand and
    US... thousand respectively for the year 2014,
    increasing from US... thousand and US..
    thousand respectively in the previous fiscal
    year.
  • The median cost of orphan drugs per patient
    reached US.. thousand in the year 2014,
    increasing from US.. thousand in the previous
    fiscal.

Global Orphan Drugs Market by Type (2014)
The U.S. Prescription Pain Market Share by
Product Value (2014)
4
The significant factors driving growth include
governmental financial incentives including tax
credits, shorter clinical trial times with
smaller trial sizes, higher rate of regulatory
success and longer exclusivity periods
Non-Hodgkins Lymphoma (NHL) Incidence by Country
(2014)
  • The total incidence for NHL reached thousand in
    the major economies increasing from thousand
    recording an annual growth of .
  • The total spending on branded orphan drugs in the
    U.S. was estimated to have reached US... billion
    in the year 2014, increasing from US... billion
    in the previous fiscal year.
  • The prevalence of LEMS (Lambert-Eaton Myasthenic
    Syndrome) in the U.S. was estimated to have
    reached in the year 2015, with a further
    expectation of reaching by the end of year 2020.
  • The market for Firdapse drug for the treatment of
    LEMS in the U.S. is expected to start with sales
    worth US.. million in 2016, and reach US..
    million by the end of 2022.

The U.S. Orphan Drugs Spending (2009-2014E)
Prevalence of LEMS in the U.S. (2015-2020E)
5
The orphan drug spending in the U.S. will rise
aided by increasing approvals for orphan drugs by
health ministry, improved medical insurance
coverage and reimbursements for the treatment of
rare diseases.
Canadian Orphan Drug Spending (2009-2014E)
  • The spending on branded orphan drugs in Canada
    was estimated to reach US.. million in the year
    2014, increasing from US... million in the
    previous fiscal year.
  • The orphan drug spending in Canada was
    anticipated to have reached US.. million in the
    year 2015, recording an annual growth of ..
    with a further expectation of reaching US..
    million by the end of year 2018.
  • The orphan drug designations per year in Japan
    reached .., increasing from .. in the previous
    fiscal year.
  • In Europe, Non-Hodgkins Lymphoma was expected to
    be the most common indication with .. orphan
    designations followed by Leukemia, acute myeloid
    (AML) with and Cystic Fibrosis (CF) with .. And
    .. designations.

Japanese Orphan Drug Designation per Year
(2009-2014)
Orphan Drug Designation in the EU by Indication
(2014)
6
Contact Us
View Report Details
These are abridged and sanitized sample pages
from the comprehensive report on the Global
Orphan Drugs Market . To know more about this
report or for any customized research
requirement, please contact the following
Koncept Analytics CS-36, Second Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T.
91-120-4130959 C 91-9811715635
vikas_at_konceptanalytics.com
Vikas Gupta BD Manager
www.konceptanalytics.com
About PowerShow.com